US National Institutes of Health: Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional) – AIDS Related

This opportunity uses the U01 Research Project – Cooperative Agreements funding mechanism.

The National Institute on Aging invites applications for its Alzheimer’s drug development programme (U01 clinical trial optional): AIDS-related.

This supports preclinical and early stage clinical development of small-molecule and biologic therapeutic agents that prevent Alzheimer’s disease, slow its progression or treat its cognitive and behavioural symptoms. Funding is for therapy development activities such as medicinal chemistry, pharmacokinetics, absorption, distribution, metabolism, excretion, toxicology, efficacy in animal models, formulation development, chemical synthesis under good manufacturing practices, investigational new drug enabling studies, and initial phase I clinical testing.

Funding & Duration

Application budgets are limited to USD $1M (approx. AUD $1.32M) in direct costs per year, and need to reflect the actual needs of the proposed project.

For Early Stage projects, the project period is limited to five years. For Late Stage projects, the project period is limited to three years.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Date

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Sciences and tagged . Bookmark the permalink.

Comments are closed.